CAR-T

China’s New CAR-T Therapy ssCART-19: Exceptional Safety with Zero ICANS Incidence

China’s New CAR-T Therapy ssCART-19: Exceptional Safety with Zero ICANS Incidence #ssCART19 #CAR_T #CART #ALL #ICANS #CNSL #CARTTherapy CAR-T therapy has reached another breakthrough with the introduction of ssCART-19, a new treatment that leverages IL-6 gene silencing technology to significantly reduce side effects, particularly when treating relapsed/refractory acute lymphoblastic leukemia (r/r ALL). Unlike traditional CAR-T Read More

September 27th,2024 CAR-T

Why More and More Foreigners Are Choosing China for CAR-T Cell Therapy

**Why More and More Foreigners Are Choosing China for CAR-T Cell Therapy** In recent years, China’s advancements in cell therapy, particularly CAR-T therapy, have been remarkable, attracting numerous international patients seeking treatment. With its cutting-edge technology, reasonable costs, and outstanding efficacy, China has become a preferred destination for cancer patients worldwide. Today, we will explore Read More

September 26th,2024 CAR-T

The Courage to Be First: China’s CAR-T Pioneer, “Emily of China,” Celebrates 6 Years in Complete Remission!

### The Courage to Be First: China’s CAR-T Pioneer, “Emily of China,” Celebrates 6 Years in Complete Remission! #CART #PatientStory #lymphoma #TP53 #DLBCL #CARTTherapy Meet Mrs. Qin, a true fighter and the first brave patient in China to receive Fosun Kite’s Axicabtagene Ciloleucel in a CAR-T clinical trial. Her story is one of hope, perseverance, Read More

September 25th,2024 patient story , CAR-T

Can the Million-dollar Anti-cancer Injection “Cure” Tumors?

Can the Million-dollar Anti-cancer Injection “Cure” Tumors? Is CAR-T therapy really a “one-shot cure”? And how can we ensure that this CAR “drives well and drives long”? 百万抗癌针能“治愈”肿瘤吗? 如何让CAR“开得好，开得久?” Expert： **Jing Pan** **Associate Chief Physician** **Department of Pediatric Hematology, Beijing Gaobo Hospital** **Professional Memberships:** – Member, Pediatric Oncology Professional Committee of the Chinese Anti-Cancer Association Read More

September 25th,2024 CAR-T

The CAR-γδT cell therapy QH104, independently developed by a Chinese team, has demonstrated a 100% disease control rate in patients with relapsed glioblastoma

**The CAR-γδT cell therapy QH104, independently developed by a Chinese team, has demonstrated a 100% disease control rate in patients with relapsed glioblastoma.** #glioblastoma #CARγδT #QH104 #γδT #B7H3 #rGBM #CARgammaT A groundbreaking CAR-γδT cell therapy, QH104, developed by a Chinese team, is gaining attention in the global medical community for its potential in treating relapsed glioblastoma (rGBM). Targeting B7H3, QH104 is Read More

September 20th,2024 Solid tumor , CAR-T

**Breakthrough in China’s CAR-T Therapy: 13-Year-Old Girl Overcomes Lupus, Opening New Hope for a Cure**

**Breakthrough in China’s CAR-T Therapy: 13-Year-Old Girl Overcomes Lupus, Opening New Hope for a Cure** #LupusTreatment #HopeForLupus #lupus #AutoimmuneDisease #ChinaHealthcare #SystemicLupusErythematosus #Erythematosus #patientstory #SLE     In June 2024, 13-year-old Qingqing experienced a major turning point in her life. A year after being diagnosed with systemic lupus erythematosus (SLE), she received innovative CAR-T therapy at Shanghai Read More

September 12th,2024 Hematological Neoplasms , CAR-T

“Curing” the Untouchable Cancer – Systemic Lupus Erythematosus: Chinese Experts Take a Major Leap Forward

**”Curing” the Untouchable Cancer – Systemic Lupus Erythematosus: Chinese Experts Take a Major Leap Forward** #LupusTreatment #HopeForLupus #lupus #AutoimmuneDisease #ChinaHealthcare #SystemicLupusErythematosus #Erythematosus Once hailed as a revolutionary therapy in the field of oncology, Chimeric Antigen Receptor T-cell (CAR-T) therapy is now demonstrating extraordinary potential in the treatment of Systemic Lupus Erythematosus (SLE). For this troublesome Read More

September 11th,2024 Solid tumor , CAR-T

China’s first BCMA CAR-T therapy successfully treats an overseas patient with advanced relapsed multiple myeloma

China’s first BCMA CAR-T therapy successfully treats an overseas patient with advanced relapsed myeloma. 🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation! WhatsApp:+8613717959070 Https://wa.me/+8613717959070 Email: doctor.huang@globecancer.com #MultipleMyeloma #CAR-T #CancerTreatment #MedicalBreakthrough #Oncology #HealthcareInnovation #BCMACART

September 2nd,2024 CAR-T

China’s Fully Human BCMA CAR-T Therapy: Bringing New Hope for High-Risk Relapsed/Refractory Multiple Myeloma

China’s Fully Human BCMA CAR-T Therapy: Bringing New Hope for High-Risk Relapsed/Refractory Multiple Myeloma Multiple Myeloma (MM) is a complex and aggressive cancer originating from plasma cells, posing significant treatment challenges due to its resistance to therapy. For patients with high-risk MM, especially those who experience relapse after multiple lines of treatment, finding an effective Read More

August 29th,2024 Myeloma , CAR-T

Chinese CAR-T Therapy: A New Frontier in Treating Systemic Lupus Erythematosus

Chinese CAR-T Therapy: A New Frontier in Treating Systemic Lupus Erythematosus #Lupus #LupusErythematosus #SystemicLupusErythematosus #CART #CARTTherapy #SLE Recently, CSPC PHARMA’s CAR-T product, SYS6020, received approval for clinical trials from China’s National Medical Products Administration (NMPA). This groundbreaking development represents a significant milestone in cell therapy, especially for treating refractory active systemic lupus erythematosus (SLE). Notably, Read More

August 15th,2024 CAR-T

**Chinese Biopharmaceuticals: Ushering in a New Era in Nasopharyngeal Carcinoma Treatment, EBV-Specific CAR-T Injection Approved for Phase II Clinical Trials in the US and China**

**Chinese Biopharmaceuticals: Ushering in a New Era in Nasopharyngeal Carcinoma Treatment, EBV-Specific CAR-T Injection Approved for Phase II Clinical Trials in the US and China** #Nasopharyngeal #Carcinoma #BRG01 #CART #EBVspecific Biosyngen has announced a milestone achievement: the company’s independently developed BRG01 injection (EBV-specific CAR-T) has received formal written approval from the U.S. Food and Drug Read More

August 14th,2024 Solid tumor , CAR-T

“Thank you,” Teresa said to the doctors and nurses with a smile, “Your professionalism and care make me feel incredibly reassured. I believe that with you by my side, I will conquer this illness.”

### Gratitude to the Doctors and Nurses at Jiahui International Hospital in Shanghai: After undergoing the processes of apheresis and reinfusion, Teresa feels immense gratitude towards the doctors and nurses at Jiahui International Hospital in Shanghai. She has deeply experienced the professionalism and care of the medical staff. Under the guidance of Dr. Vicky Lee Read More

August 7th,2024 CAR-T